Article: Lutetium Lu 177 vipivotide tetraxetan for prostate cancer.
Drugs of today (Barcelona, Spain : 1998)
2023 Volume 59, Issue 1, Page(s) 37–49
Abstract: On March 23, 2022, the U.S. Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 ... therapy for eligible men with PSMA-positive mCRPC. Lutetium Lu 177 vipivotide tetraxetan is a radioligand ... and clinical studies of the novel drug lutetium Lu 177 vipivotide tetraxetan for the treatment ...
Abstract | On March 23, 2022, the U.S. Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan), also known as 177Lu-PSMA-617, for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who have highly expressed prostate-specific membrane antigen (PSMA) and have at least one metastatic lesion. It is the first FDA-approved targeted radioligand therapy for eligible men with PSMA-positive mCRPC. Lutetium Lu 177 vipivotide tetraxetan is a radioligand that strongly binds to PSMA, making it ideal for treating cancers of the prostate by targeted radiation, resulting in DNA damage and cell death. PSMA is overexpressed in cancer cells while being lowly expressed in normal tissues, which makes it an ideal theranostic target. As precision medicine advances, this is a thrilling turning point for highly individualized treatments. This review aims to summarize the pharmacology and clinical studies of the novel drug lutetium Lu 177 vipivotide tetraxetan for the treatment of mCRPC, emphasizing its mechanism of action, pharmacokinetics and safety. |
---|---|
MeSH term(s) | Male ; Humans ; Lutetium/adverse effects ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostate-Specific Antigen/therapeutic use ; Treatment Outcome |
Chemical Substances | 177Lu-PSMA-617 ; 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid (1HTE449DGZ) ; Lutetium (5H0DOZ21UJ) ; Prostate-Specific Antigen (EC 3.4.21.77) |
Language | English |
Publishing date | 2023-02-22 |
Publishing country | Spain |
Document type | Review ; Journal Article |
ISSN | 1699-3993 |
ISSN | 1699-3993 |
DOI | 10.1358/dot.2023.59.1.3476574 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Inter-library loan at ZB MED
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.